We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

AI-Powered H&E Analyzer Predicts Immunotherapy Treatment Outcomes in Lung Cancer

By LabMedica International staff writers
Posted on 05 Sep 2023
Print article
Image: Tertiary lymphoid structures analysis has shown potential as an emerging biomarker for lung cancer treatment (Photo courtesy of 123RF)
Image: Tertiary lymphoid structures analysis has shown potential as an emerging biomarker for lung cancer treatment (Photo courtesy of 123RF)

A groundbreaking study has demonstrated that artificial intelligence (AI) analysis of Tertiary Lymphoid Structures (TLS) in tumors can predict treatment response in patients with non-small cell lung cancer (NSCLC).

The study explored the use of Lunit’s (Seoul, South Korea) Lunit SCOPE IO, an AI-powered Hematoxylin and Eosin (H&E) analyzer designed to identify TLS in the tumor microenvironment (TME), to predict the outcomes of immunotherapy in lung cancer cases. Lunit SCOPE is a suite of AI-driven software that analyzes digital pathology images of tissue slides and aids in the development of AI biomarkers. It aims to enhance workflows and provide clinicians and researchers with more precise and anticipatory clinical data. Lunit SCOPE IO was created using a vast dataset of H&E-stained whole-slide images sourced from 18 different cancer types across the world. The platform encompasses various AI-based tissue analysis tools and assays intended to optimize digital pathology workflows, diagnostics, and drug development. Lunit SCOPE IO assesses the TME using H&E analysis and delivers AI-driven prognostic clinical outcome insights. Additionally, AI-fueled Immunohistochemistry (IHC) slide analysis services are available, including Lunit SCOPE PD-L1, Lunit SCOPE HER2, Lunit SCOPE ER/PR, and others.

The new study builds on earlier research findings indicating that the presence of TLS could function as a predictive marker for the efficacy of immuno-oncology treatment. The study analyzed a cohort of 85 NSCLC patients who were administered immune checkpoint inhibitors (ICI). The results revealed that leveraging Lunit SCOPE IO for TLS assessment established clinically substantial correlations with patients' overall survival (OS). Notably, among the patients with detected TLS, 25 exhibited significantly extended overall survival compared to the 60 patients without TLS. This correlation persisted irrespective of PD-L1 expression, a recognized biomarker for treatment response in NSCLC patients. These findings underscore the potential of AI-guided TLS analysis as a biomarker to forecast treatment response in individuals with NSCLC.

"Through rigorous collaboration and cutting-edge technology, our study illuminates a promising path toward better predicting lung cancer treatment outcomes,” said Brandon Suh, CEO of Lunit. “The potential of TLS analysis via Lunit SCOPE IO in predicting immunotherapy response represents a meaningful step forward in better understanding cancer biology, and making AI analysis of the TME an actionable part of cancer care."

Related Links:

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Plasma Control
Plasma Control Level 1

Print article


Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more


view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.